Breakthrough T1D

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging bio

Advantagene Closes $14.2m Series A Round Immuno-oncology firm Advantagene Inc. raised $14.2m through the sale of its Series A convertible preferred shares to undisclosed investors. National Securi

Biopharma start-ups brought in half as much funding in the third quarter as in the second quarter, but the number of alliances for new and emerging therapeutics firms stayed the same. Big pharma made

IN VITRO DIAGNOSTICS Financings Quotient Ltd. Quotient Ltd. netted $45.4mm through a public sale of 8mm ordinary shares (including the overallotment) at $6. Funds will support ongoing scale-up and